Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

INTRODUCTION: Hypercoagulability in malignancy increases the risk of thrombosis, but is also involved in cancer progression. Experimental studies suggest that tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are involved in cancer biology as a tumor- promoter and suppressor, respectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinholt, Mari, Vollan, Hans Kristian Moen, Sahlberg, Kristine Kleivi, Jernström, Sandra, Kaveh, Fatemeh, Lingjærde, Ole Christian, Kåresen, Rolf, Sauer, Torill, Kristensen, Vessela, Børresen-Dale, Anne-Lise, Sandset, Per Morten, Iversen, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423106/
https://www.ncbi.nlm.nih.gov/pubmed/25882602
http://dx.doi.org/10.1186/s13058-015-0548-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423106/
https://www.ncbi.nlm.nih.gov/pubmed/25882602
http://dx.doi.org/10.1186/s13058-015-0548-5

Ejemplares similares